Comparison of Approaches to Stability Testing of Medicines in the Russian Federation and the Eurasian Economic Union

Stability testing gives necessary data on the effect of such factors as temperature, light, humidity, etc. on the medicinal product quality. The results of these studies help to select suitable primary and secondary packaging and to determine storage conditions and shelf life for the product. The aim of this study was to compare current requirements for stability testing of medicinal products in the Russian Federation and the Eurasian Economic Union (EAEU). The study covered stability testing of small-molecule medicines. The paper describes evolution of approaches to stability testing in the Russian Federation. It summarises the main differences in basic requirements for stability testing as stipulated in the State Pharmacopoeia of the Russian Federation (Ph. Rus.) XIII edition, Ph. Rus. XIV edition, and EAEU regulations. The study demonstrated that the Russian Federation lacks regulations containing specific requirements for stability testing performed to support variations to marketing authorisation documentation. The Ph. Rus. XIV edition does not specify the extent of stability testing to be performed after switching to another manufacturer of the active ingredient or introduction into operation of a new manufacturing site where the medicinal product will be produced. At the same time, the EAEU regulatory documents contain requirements for stability testing for each type of the most frequent variations to marketing authorisation documentation. The study demonstrated the continuing relevance of bringing the Russian regulations on stability testing in line with those of the EAEU.

1. Sakaeva IV, Bunyatyan ND, Kovaleva EL, Sakanyan EI, Mit’kina LI, Prokopov IA, et al. Basic approaches to drug stability studies: domestic and international experience. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2013;(3):8–11 (In Russ.)

2. Meshkovsky AP. World Health Organization guidelines for studying the stability of generic pharmaceutical products. Pharmateca = Farmateka. 1995;(6):12–15 (In Russ.)

3. Rudakova IP. On WHO recommendations for studying the stability of generic pharmaceutical products. Pharmateca = Farmateka. 1996;(1):39–40 (In Russ.)

4. Mashkovsky MD. Stability and shelf life of medicines are relevant issues in Russia. Pharmateca = Farmateka. 1996;(1):38 (In Russ.)

5. Meshkovsky AP. Regulatory issues in setting expiry dates for medicinal products. Remedium = Remedium. 2008;(3):36–9 (In Russ.)

6. Meshkovsky AP. Stability testing and establishing shelf lives of medicinal products. Pharmateca = Farmateka. 2000;(2):25–34 (In Russ.)

7. Prokopov IA, Kovaleva EL, Mit’kina LI, Shanazarov KS. Stability issues of drugs, relationship with primary packaging. Razrabotka i registratsiya lekarstvennykh sredstv = Drug Development and Registration. 2014;(4):198–202 (In Russ.)

8. Chekryshkina LA, Babikova EA, Slepova NV. The study of stability and establishment of shelf-life of the substance of monomekaine. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2015;(2-2):485 (In Russ.)

9. Mit’kina LI, Kovaleva EL, Prokopov IA. Stress studies and photostability as a part of pharmaceutical drug development data. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(2):9–12 (In Russ.)

10. Bott RF, Oliveira WP. Storage conditions for stability testing of pharmaceuticals in hot and humid regions. Drug Dev Ind Pharm. 2007;33(4):393–401. https://doi.org/10.1080/03639040600975022

11. Ermolaeva II, Popova TV, Kotlyar MA. Study of the stability of drugs. Izvestiya GGTU. Meditsina, farmatsiya = Proceedings of GGTU. Medicine, Pharmacy. 2020;(4):109–11 (In Russ.)